184 related articles for article (PubMed ID: 19010449)
1. The new immunosuppressive agent FK778 attenuates neointima formation in an experimental venous bypass graft model.
de Graaf R; Kloppenburg G; Tintu A; Rouwet E; Kitslaar P; van Hooff J; Bruggeman C; Stassen F
Vascul Pharmacol; 2009; 50(3-4):83-8. PubMed ID: 19010449
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides?
Schrepfer S; Deuse T; Sultan KR; Haddad M; Böger R; Münzel T; Schäfer H; Pelletier MP; Robbins RC; Reichenspurner H
Cardiology; 2007; 108(2):128-37. PubMed ID: 17028423
[TBL] [Abstract][Full Text] [Related]
3. FK778 attenuates cytomegalovirus-enhanced vein graft intimal hyperplasia in a rat model.
Kloppenburg G; de Graaf R; Grauls G; Bruggeman CA; van Hooff JP; Stassen F
Intervirology; 2009; 52(4):189-95. PubMed ID: 19546576
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine prevents neointima formation in experimental venous bypass grafts.
de Graaf R; Tintu A; Stassen F; Kloppenburg G; Bruggeman C; Rouwet E
Br J Surg; 2009 Aug; 96(8):941-50. PubMed ID: 19591160
[TBL] [Abstract][Full Text] [Related]
5. 2005 Dr. Gary J. Becker Young Investigator Award: periprocedural oral administration of the leflunomide analogue FK778 inhibits neointima formation in a double-injury rat model of restenosis.
Jahnke T; Schäfer FK; Bolte H; Rector L; Schäfer PJ; Brossmann J; Fändrich F; Hedderich J; Heller M; Müller-Hülsbeck S
J Vasc Interv Radiol; 2005 Jul; 16(7):903-10. PubMed ID: 16002499
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus and FK778: a comparison of two anti-proliferative immunosuppressants for prevention of experimental obliterative airway disease.
Deuse T; Schrepfer S; Koch-Nolte F; Haddad M; Schäfer H; Detter C; Reichenspurner H
Transpl Int; 2006 Apr; 19(4):310-8. PubMed ID: 16573547
[TBL] [Abstract][Full Text] [Related]
7. FK778: new cellular and molecular mechanisms of action.
Schrepfer S; Deuse T; Koch-Nolte F; Detter C; Reichenspurner H
Transplant Proc; 2006 Apr; 38(3):757-61. PubMed ID: 16647464
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection.
Savikko J; Von Willebrand E; Häyry P
Transplantation; 2003 Aug; 76(3):455-8; discussion 471-3. PubMed ID: 12923428
[TBL] [Abstract][Full Text] [Related]
9. FK778 and tacrolimus prevent the development of obliterative airway disease after heterotopic rat tracheal transplantation.
Deuse T; Schrepfer S; Koch-Nolte F; Haddad M; Schwedhelm E; Böger R; Schäfer H; Detter C; Reichenspurner H
J Heart Lung Transplant; 2005 Nov; 24(11):1844-54. PubMed ID: 16297791
[TBL] [Abstract][Full Text] [Related]
10. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts.
Pan F; Ebbs A; Wynn C; Erickson L; Jang MS; Crews G; Fisniku O; Kobayashi M; Paul LC; Benediktsson H; Jiang AH
Transplantation; 2003 Apr; 75(8):1110-4. PubMed ID: 12717186
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral activin A expression prevents vein graft intimal hyperplasia in a rat model.
Kloppenburg GT; Grauls GE; Bruggeman CA; Stassen FR
Interact Cardiovasc Thorac Surg; 2009 Jan; 8(1):31-4. PubMed ID: 18854336
[TBL] [Abstract][Full Text] [Related]
12. Periadventitial rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts.
Rajathurai T; Rizvi SI; Lin H; Angelini GD; Newby AC; Murphy GJ
Circ Cardiovasc Interv; 2010 Apr; 3(2):157-65. PubMed ID: 20332383
[TBL] [Abstract][Full Text] [Related]
13. The effect of FK778 on acute rat renal allograft rejection and expression of platelet-derived growth factor and transforming growth factor-beta.
Rintala JM; Savikko J; Rintala SE; von Willebrand E
Transplant Proc; 2006 Oct; 38(8):2719-21. PubMed ID: 17098049
[TBL] [Abstract][Full Text] [Related]
14. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts.
Rintala JM; Savikko J; Rintala SE; von Willebrand E
Nephrol Dial Transplant; 2008 Nov; 23(11):3446-55. PubMed ID: 18558624
[TBL] [Abstract][Full Text] [Related]
15. Bypass graft disease: analysis of proliferative activity in human aorto-coronary bypass grafts.
Hilker M; Buerke M; Lehr HA; Oelert H; Hake U
Heart Surg Forum; 2002; 5 Suppl 4():S331-41. PubMed ID: 12759206
[TBL] [Abstract][Full Text] [Related]
16. Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens.
Millán O; Jiménez O; Fortuna V; Barceló JJ; Brunet M
Int J Immunopathol Pharmacol; 2006; 19(2):317-30. PubMed ID: 16831299
[TBL] [Abstract][Full Text] [Related]
17. FK778, a novel immunosuppressive agent, reduces early adhesion molecule up-regulation and prolongs cardiac allograft survival.
Schrepfer S; Deuse T; Schäfer H; Reichenspurner H
Transpl Int; 2005 Feb; 18(2):215-20. PubMed ID: 15691275
[TBL] [Abstract][Full Text] [Related]
18. Reduced neointima in vein grafts following a blockage of cell recruitment from the vein and the surrounding tissue.
Fogelstrand P; Osterberg K; Mattsson E
Cardiovasc Res; 2005 Aug; 67(2):326-32. PubMed ID: 15885671
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts.
Vu MD; Qi S; Wang X; Jiang W; Ma A; Xu D; Bekersky I; Fitzsimmons WE; Wu J; Chen H
Transplantation; 2003 May; 75(9):1455-9. PubMed ID: 12792496
[TBL] [Abstract][Full Text] [Related]
20. FK778 in experimental xenotransplantation: a detailed analysis of drug efficacy.
Schrepfer S; Deuse T; Koch-Nolte F; Krieger T; Haddad M; Schäfer H; Pelletier MP; Robbins RC; Reichenspurner H
J Heart Lung Transplant; 2007 Jan; 26(1):70-7. PubMed ID: 17234520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
